Maculopapular Exanthema After the Second Dose of Evolocumab

Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin ras...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghernautan, Victoria, Amini, Masoud, Sachmechi, Issac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229243/
https://www.ncbi.nlm.nih.gov/pubmed/34188988
http://dx.doi.org/10.7759/cureus.15249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229243/
https://www.ncbi.nlm.nih.gov/pubmed/34188988
http://dx.doi.org/10.7759/cureus.15249

Ejemplares similares